XTX Topco Ltd Makes New $596,000 Investment in Integer Holdings Co. (NYSE:ITGR)

XTX Topco Ltd bought a new position in shares of Integer Holdings Co. (NYSE:ITGR) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,144 shares of the medical equipment provider’s stock, valued at approximately $596,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ITGR. Norges Bank bought a new position in Integer during the fourth quarter worth about $18,697,000. Coldstream Capital Management Inc. bought a new position in shares of Integer during the 4th quarter valued at about $229,000. US Bancorp DE lifted its holdings in shares of Integer by 2.4% during the 4th quarter. US Bancorp DE now owns 14,837 shares of the medical equipment provider’s stock valued at $1,470,000 after purchasing an additional 347 shares in the last quarter. Connable Office Inc. lifted its holdings in shares of Integer by 22.6% during the 4th quarter. Connable Office Inc. now owns 5,626 shares of the medical equipment provider’s stock valued at $557,000 after purchasing an additional 1,037 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its holdings in shares of Integer by 345.9% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 11,900 shares of the medical equipment provider’s stock valued at $1,179,000 after purchasing an additional 9,231 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ITGR shares. Oppenheimer started coverage on Integer in a report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price objective on the stock. Benchmark reiterated a “buy” rating and set a $130.00 price objective on shares of Integer in a report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $133.86.

Insiders Place Their Bets

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now owns 2,280 shares of the company’s stock, valued at approximately $272,824.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company’s stock.

Integer Stock Down 0.7 %

Shares of Integer stock opened at $128.39 on Tuesday. The business’s 50 day simple moving average is $123.15 and its 200 day simple moving average is $118.75. Integer Holdings Co. has a 52-week low of $69.40 and a 52-week high of $131.87. The firm has a market cap of $4.30 billion, a PE ratio of 44.43, a P/E/G ratio of 1.81 and a beta of 1.09. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million for the quarter, compared to analyst estimates of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. Integer’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. On average, analysts predict that Integer Holdings Co. will post 5.31 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.